Jeffery Russell, MD, PhD

Dr. Russell earned his MD degree from the University of Texas Health Science Center at San Antonio. He completed an Internal Medicine Residency at the University of California - San Francisco in 2010. Dr. Russell earned his PhD with a focus in Radiation Biology at the University of Texas – Houston Health Science Center – MD Anderson Cancer Center. He recently completed a Medical Oncology Fellowship at Stanford University. Dr. Russell’s clinical focus is on head and neck and endocrine cancers including: squamous cell carcinoma of the mouth and throat, nasopharyngeal carcinoma, salivary gland carcinoma, thyroid carcinoma, and other rare neoplasms of the head and neck and endocrine system. Additionally, Dr. Russell has an interest in managing advanced squamous cell carcinoma of the skin. Through translational studies and clinical trials, he plans to explore the use of novel agents to enhance radiation responsiveness of the tumors and to reduce the risk of the metastatic spread of these diseases. Dr. Russell will continue to study the role of circulating vascular cells (vasculogenesis) within the tumor microenvironment as a novel mechanism of resistance to radiation therapy.

Provider

Jeffery Russell, MD, PhD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Head and Neck-Endocrine Oncology

Print Print Physician Bio

Education & Training

BOARD CERTIFICATION:
  • Internal Medicine
FELLOWSHIP:
  • Stanford University - Medical Oncology
RESIDENCY:
  • University of California - San Francisco - Internal Medicine
MEDICAL SCHOOL:
  • University of Texas - Health Center at San Antonio - MD
Provider

Jeffery Russell, MD, PhD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Head and Neck-Endocrine Oncology

Print Print Physician Bio

Publications

  • Gay LM, Kim S, Fedorchak K, Kundranda M, Odia Y, Nangia C, Battiste J, Colon-Otero G, Powell S, Russell J, Elvin JA, Vergilio JA, Suh J, Ali SM, Stephens PJ, Miller VA, Ross JS. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. Oncologist. 2017 May. Pubmedid: 28495808.
  • Knepper TC, Freeman ML, Gibney GT, McLeod HL, Russell JS. Clinical Response to Pazopanib in a Patient With KDR-Mutated Metastatic Basal Cell Carcinoma. JAMA Dermatol. 2017 Jun;153(6):607-609. Pubmedid: 28384659.
  • Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, Sondak VK, Padhya TA, Trotti AM, Caudell JJ, Harrison LB. Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck. 2017 Jan;39(1):48-55. Pubmedid: 27300153.
  • Strom TJ, Naghavi AO, Trotti AM, Russell J, Kish JA, McCaffrey J, Otto KJ, Harrison LB, Caudell JJ. Increased acute mortality with chemoradiotherapy for locally advanced head and neck cancer in patients ≥70years. Geriatr Oncol. 2017 Jan;8(1):50-55. Pubmedid: 27720129.
  • Valderrabano P, Montilla Soler J, Mifsud MJ, Leon ME, Centeno BA, Khazai L, Padhya T, McCaffrey TV, Russell JS, McIver B, Otto KJ. Hypermetabolism on (18)F-Fluorodeoxyglucose Positron Emission Tomography Scan Does Not Influence the Interpretation of Thyroid Cytopathology, and Nodules with a SUVmax <2.5 Are Not at Increased Risk for Malignancy. Thyroid. 2016 Sep;26(9):1300-1307. Pubmedid: 27324615.
  • Naghavi AO, Strom T, Abuodeh YA, Echevarria M, Russell J, Kish JA, Balducci L, Trotti A, Harrison LB, Caudell JJ. Concurrent Chemotherapy in Elderly Patients With Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E362. Pubmedid: 27674484.
  • Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M, Brownell I, Lewis KD, Lorch JH, Chin K, Mahnke L, von Heydebreck A, Cuillerot JM, Nghiem P. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016 Oct;17(10):1374-1385. Pubmedid: 27592805.
  • Strom T, Carr M, Zager JS, Naghavi A, Smith FO, Cruse CW, Messina JL, Russell J, Rao NG, Fulp W, Kim S, Torres-Roca JF, Padhya TA, Sondak VK, Trotti AM, Harrison LB, Caudell JJ. Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Ann Surg Oncol. 2016 Oct;23(11):3572-3578. Pubmedid: 27251134.
  • Lowry PA, Freeman ML, Russell JS. Nursing Management of Advanced Merkel Cell Carcinoma. Oncol Nurs Forum. 2016 Nov;43(6):680-683. Pubmedid: 27768129.
  • Valderrabano P, Leon ME, Centeno BA, Otto KJ, Khazai L, McCaffrey JC, Russell JS, McIver B. Institutional prevalence of malignancy of indeterminate thyroid cytology is necessary but insufficient to accurately interpret molecular marker tests. Eur J Endocrinol. 2016 May;174(5):621-629. Pubmedid: 26903551.
  • Frakes JM, Naghavi AO, Demetriou SK, Strom TJ, Russell JS, Kish JA, McCaffrey JC, Otto KJ, Padhya TA, Harrison LB, Trotti AM, Caudell JJ. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer. Cancer. 2016 Feb;122(4):634-641. Pubmedid: 26565997.
  • Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clin Cancer Res. 2016 Dec;22(24):6061-6068. Pubmedid: 27334835.
  • Strom TJ, Trotti AM, Kish J, Russell JS, Rao NG, McCaffrey J, Padhya TA, Otto KJ, Caudell JJ. Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer. Oral Oncol. 2015 Jul;51(7):704-708. Pubmedid: 25936651.
  • Metterle L, Russell JS, Patel NS. An overview of the medical management of nonmelanoma skin cancer. Curr Prob Cancer. 2015 Aug;39(4):226-236. Pubmedid: 26277493.
  • Russell JS, Brown JM. Circulating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts. Mol Cancer. 2014 Jul;13:177. Pubmedid: 25047738. Pmcid: PMC4112847.
  • Russell JS, Brown JM. The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front Physiol. 2013 Jul;4:157. Pubmedid: 23882218. Pmcid: PMC3713331.
  • Russell JS, Colevas AD . The use of epidermal growth factor receptor monoclonal antibodies in squamous cell carcinoma of the head and neck. Chemother Res Pract. 2012 Nov;2012:761518. Pubmedid: 23150825. Pmcid: PMC3488396.
  • Russell JS, Sawhney R, Monto A, Nanavati S, Davoren JB, Aslam R, Corvera CU. Periprocedural complications by Child-Pugh class in patients undergoing transcatheter arterial embolization or chemoembolization to treat unresectable hepatocellular carcinoma at a VA medical center. Am J Surg. 2010 Nov;200(5):659-664.
  • Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther. 2004 Apr;3(4):409-416.
  • Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res. 2003 Sep;9:3749-3755.
  • Russell JS, Brady K, Burgan WE, Cerra MA, Oswald KA,, Camphausen K, Tofilon PJ. Gleevec-mediated inhibition of Rad51 expression and enhancement of tumor cell radiosensitivity. Cancer Res. 2003 Nov;63(21):7377-7383.
  • Russell JS, Tofilon PJ. Radiation-induced activation of nuclear factor-kappaB involves selective degradation of plasma membrane-associated I(kappa)B(alpha). Mol Biol Cell. 2002 Oct;13(10):3431-3140. Pmcid: PMC129956.
  • Russell JS, Raju U, Gumin GJ, Lang FF, Wilson DR, Huet T, Tofilon PJ. Inhibition of radiation-induced nuclear factor-kappaB activation by an anti-Ras single-chain antibody fragment: lack of involvement in radiosensitization. Cancer Res. 2002 Apr;62(8):2318-2326.
  • Russell JS, Lang FF, Huet T, Janicot M, Chada S, Wilson DR, Tofilon PJ. Radiosensitization of human tumor cell lines induced by the adenovirus-mediated expression of an anti-Ras single-chain antibody fragment. Cancer Res. 1999 Oct;59(20):5239-5244.
  • Wu X, Ting JY, Markoe AM, Landy HJ, Fiedler JA, Russell J. Stereotactic dose computation and plan optimization using the convolution theorem. I. Dose computation. Stereot Funct Neuros. 1996;66(Suppl 1):302-308.

Provider

Jeffery Russell, MD, PhD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Head and Neck-Endocrine Oncology

Print Print Physician Bio

Participating Trials

CLINICAL TRIAL 17938
A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of MSB0010718C in Subjects with Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: MSB00100718C (Avelumab); Not Applicable
Open

CLINICAL TRIAL 18587
A Phase 2 Study of REGN2810, A Fully Human Monoclonal Antibody to Programmed Death 1(PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma
Condition: Head & Neck
Intervention: REGN2810
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18527
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherpay and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Not Applicable; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 18902
A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Condition: Head & Neck
Intervention: Avelumab; MSB00100718C (Avelumab); Placebo; Radiotherapy; cisplatin
Open

CLINICAL TRIAL 18838
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Head & Neck
Intervention: 5-fluorouracil; BMS-936558 (Nivolumab); Cetuximab; Erbitux (Cetuximab); Ipilimumab; Nivolumab; Paraplatin (carboplatin); Yervoy (Ipilimumab); carboplatin; cisplatin
Open

CLINICAL TRIAL 18839
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Condition: Head & Neck
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Placebo; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17716
A Biomarker-related Approach to Screening for HPV-related Oropharyngeal Cancer
Condition: Head & Neck
Intervention:
Open

CLINICAL TRIAL 17799
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck
Condition: Head & Neck
Intervention: cisplatin
Open

CLINICAL TRIAL 17937
A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab; Not Applicable; Urelumab
Open

CLINICAL TRIAL 18309
A Phase 2, Multicenter, Single-arm Study to Assess the Safety, Feasibility, and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-144) Followed by IL-2 for Treatment of Metastatic Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); IL-2 (Interleukin-2); Interleukin-2; Proleukin (Interleukin-2); TIL
Open

CLINICAL TRIAL 18612
A Randomized Phase II/III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Condition: Head & Neck
Intervention: cisplatin
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 18686
An Observational Pilot Study to Compare the Compliance with and Health Related Quality of Life during Therapy with Standard High-Dose Interferon Alfa (Intron® A, HDI) versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients with Surgically Resected Melanoma
Condition: Cutaneous
Intervention: PEG-Intron (Peginterferon Alfa 2B); interferon alfa
Open

CLINICAL TRIAL 17974
An Open-Label, Multicenter, Dose-Escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; RTA 408; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17986
Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Condition: Multiple
Intervention: CP-675,206 (tremelimumab); KW-0761 (Mogamulizumab); MEDI4736 (Durvalumab); Mogamulizumab; Not Applicable; tremelimumab
Open

CLINICAL TRIAL 18227
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Condition: Head & Neck
Intervention: 5-fluorouracil; Gemzar (gemcitabine); Not Applicable; Taxol (paclitaxel); cisplatin; gemcitabine; paclitaxel
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022
Open

CLINICAL TRIAL 18874
A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); HBI-8000 (chidamide); Nivolumab
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 18832
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Condition: Multiple
Intervention: Epacadostat; INCB024360 (Epacadostat); INCB039110; INCB050465
Open

CLINICAL TRIAL 18922
A US Multisite Observational Study in Patients with Unresectable and Metastatic Melanoma: the OPTIMIzE Study
Condition: Cutaneous
Intervention: Not Applicable
Open

CLINICAL TRIAL 18922
A US Multisite Observational Study in Patients with Unresectable and Metastatic Melanoma: the OPTIMIzE Study
Condition: Cutaneous
Intervention: Not Applicable
Open

CLINICAL TRIAL 18062
Impact of Ancillary Techniques in the Pre-Surgical Diagnosis of Thyroid Nodules.
Condition: Head & Neck
Intervention:
Open

CLINICAL TRIAL 18561
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18944
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Head & Neck
Intervention: IL-2 (Interleukin-2); LN-145; MESNA; TIL; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 18377
A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2; Nivolumab; Proleukin (Interleukin-2); TIL
Open

CLINICAL TRIAL 18933
Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Cutaneous
Intervention: Ipilimumab; Pembrolizumab (Keytruda); Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).


Provider

Jeffery Russell, MD, PhD

Medical Oncology

Call 1-888-Moffitt
(1-888-663-3488)
For an Appointment

Schedule Appointment

Program
Head and Neck-Endocrine Oncology

Print Print Physician Bio